Top 5 Articles About Healthcare and Drug Costs in 2023
Articles about Humira biosimilars, over-the-counter hearing aids and specialty drugs were among those about healthcare and drug costs that had the most pageviews on the MHE website in 2023.
Here are the top five most-viewed articles about healthcare and drug costs that were posted on the Managed Healthcare Executive website in 2023.
The Future of Savings in Humira Biosimilars Drug Costs Are Low
As a Humira biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.
No Prescription Needed. But Will Insurers Cover OTC Hearing Aids?
Commercial plans haven’t traditionally covered hearing aids.
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.
Inpefa, a New Heart Failure Drug, Surpasses Cost-Effectiveness Threshold
Inpefa (sotagliflozin) added 0.39 quality of life years at an incremental lifetime cost of $29,449 for an incremental cost-effectiveness ratio of $75,510 per quality-of-life year gained, according to the study that was sponsored by the drug's maker, Lexicon Pharmaceuticals.
Off-label Use of Avastin in Diabetic Macular Edema More Cost-Effective Than Eylea
Starting with Avastin to treat patients with diabetic macular edema — and switching to Eylea if patients don’t have a response — could result in savings of more than $125 million.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
